Novabay Pharmaceuticals (NBY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 9,781 | 10,455 | 14,404 | 10,204 | 9,934 |
| Cost of Goods | 3,300 | 4,371 | 6,623 | 3,689 | 3,970 |
| Gross Profit | 6,481 | 6,084 | 7,781 | 6,515 | 5,964 |
| Operating Expenses | 12,620 | 10,557 | 22,821 | 16,066 | 13,360 |
| Operating Income | -5,839 | -4,102 | -14,417 | -8,862 | -6,426 |
| Other Income | -1,371 | -2,043 | 3,809 | 3,038 | -4,608 |
| Pre-tax Income | -7,210 | -6,145 | -10,608 | -5,824 | -11,034 |
| Income Tax | N/A | N/A | N/A | N/A | -5 |
| Net Income Continuous | -7,210 | -6,145 | -10,608 | -5,824 | -11,029 |
| Net Income Discontinuous | -13 | -3,495 | N/A | N/A | N/A |
| Net Income | $-7,223 | $-9,640 | $-10,608 | $-5,824 | $-11,029 |
| EPS Basic Total Ops | -2.53 | -139.14 | -353.15 | -183.92 | -378.99 |
| EPS Basic Continuous Ops | -2.53 | -110.02 | -230.38 | -163.30 | -384.41 |
| EPS Basic Discontinuous Ops | 0.00 | -29.12 | N/A | N/A | N/A |
| EPS Diluted Total Ops | -2.53 | -139.14 | -353.15 | -183.92 | -378.99 |
| EPS Diluted Continuous Ops | -2.53 | -110.02 | -230.38 | -163.30 | -384.41 |
| EPS Diluted Discontinuous Ops | 0.00 | -29.12 | N/A | N/A | N/A |
| EPS Diluted Before Non-Recurring Items | -2.53 | -117.13 | -353.15 | -183.38 | -378.99 |
| EBITDA(a) | $-5,799 | $-4,051 | $-7,197 | $-8,743 | $-6,375 |